WIRE — THE Court of Tax Appeals (CTA) en banc upheld the denial of Zuellig Pharma Asia Pacific Ltd. Phils. ROHQ's P59.81-million value-added tax (VAT) refund claim after finding that the company failed to satisfy documentary requirements for zero-rated sales. In a decision promulgated on July 9, the tax court affirmed an earlier ruling denying the company's
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.